Trial Profile

Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SP 0253 (Primary) ; Adjuvants
Indications COVID 2019 infections
Focus Adverse reactions; First in man; Pharmacodynamics
Sponsors Sanofi; Sanofi Pasteur

Most Recent Events

23 Dec 2021 Status changed from active, no longer recruiting to completed.
01 Sep 2021 Interim results reporting safety and immunogenicity data up to 43 days after the first vaccination published in The Lancet Infectious Diseases
27 May 2021 According to a Sanofi media release, first results from this study are expected in the third quarter of 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com